Pulsenmore Ltd. (PLSM)
AI stock analysis · as of Jul 14, 2026
Loading microstructure…
Pulsenmore is a micro-cap ($23.5M) Israeli medical device company commercializing FDA-authorized home ultrasound devices (Pulsenmore ES/FC). FY2025 revenue exploded to $40M from $9.7M (+314% YoY) with gross margin jumping to 84% from 37%, suggesting an inflection in commercial adoption — but the company remains deeply unprofitable (-$15.9M net income, -$33M FCF) with only $21.6M cash and ongoing dilution overhang. The core investment question: is the FY2025 revenue ramp the start of durable, high-margin scaling that justifies re-rating from current depressed levels, or a one-off tied to a specific contract that will not repeat, leaving a cash-burning micro-cap facing dilution?
valuationRoughly fair-to-cheap on headline P/S (~0.6x on FY25 revenue) given 84% gross margins and triple-digit growth, but the multiple is distorted by uncertainty over revenue durability and dilution — hard to anchor without forward guidance or analyst estimates.
This analysis is from Jul 14, 2026. Want the latest on PLSM, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Revenue grew 314% YoY in FY2025 to $40M with gross margin expanding dramatically from 37% to 84%, indicating operating leverage as the platform scales
- · Net loss narrowed materially from -$36.7M (FY24) to -$15.9M (FY25) despite the revenue jump, showing improving unit economics
- · Fresh $7.5M private placement from a healthcare-specialist investor validates the story and extends runway alongside $21.6M cash vs. only $1.6M debt
- · Positive catalyst cluster: selected to lead a $1M Israel Healthcare AI Sandbox project and signed a partnership with Ouma's maternity care platform, expanding the addressable channel
- · Stock trades at $3.62 vs. a 52-week high of $12.97 — near the $3.00 low — offering asymmetric upside if commercial momentum persists
- · High insider ownership (43.4%) aligns management with shareholders
Bear case
- · Warrant registration (3.1M shares) plus Armistice reselling 3.125M shares creates significant near-term dilution and supply overhang on a ~6.5M share float equivalent
- · Free cash flow of -$33M against $21.6M cash implies less than a year of runway absent the recent raise; further capital raises likely
- · Debt-to-equity of 1.88 is high for a company with negative earnings and shrinking equity from persistent losses
- · Revenue quality is unproven: the 314% jump could reflect a lumpy contract rather than recurring device sales; no analyst coverage means limited visibility
- · Governance concerns flagged in news flow (AGM cancellation) and thin liquidity make the stock vulnerable to momentum-driven whipsaws
- · Institutional ownership is negligible (5.2%), suggesting professional investors have not underwritten the story
Catalysts
- · Next quarterly report — confirmation that the FY2025 revenue run-rate is durable rather than a one-time contract
- · Deliverables and any commercial spinouts from the Israel Healthcare AI Sandbox $1M project
- · Rollout milestones and enrollment data from the Ouma maternity care partnership
- · Resolution/absorption of the Armistice resale and warrant registration overhang
- · Additional strategic partnerships or U.S. payer coverage announcements for the home ultrasound device
Key risks
- · Dilution from warrant exercises and Armistice resale pressuring the share price regardless of fundamentals
- · Cash burn requiring another equity raise at depressed prices
- · Revenue concentration/lumpiness — the FY25 spike may not repeat in FY26
- · Micro-cap illiquidity and momentum-driven volatility disconnecting price from fundamentals
- · Governance/execution risk following AGM cancellation and given the sub-$25M market cap scale
What to watch
- · Next earnings release for FY25 revenue composition and any FY26 outlook commentary
- · Form filings tracking Armistice resale progress and warrant exercise activity
- · Support at the 52-week low of $3.00 — a breach could trigger further momentum selling
- · Any 6-K disclosing new commercial contracts, U.S. distribution deals, or payer coverage
- · Cash position updates and any signal of an incremental capital raise
Key metrics
Price target rationale
Base case ~$4.25 applies ~1.0x FY25 sales on ~27M diluted shares (post-warrant/resale), a modest premium reflecting 84% gross margins but discounted for cash burn. Bull ~$7.50 assumes FY25 revenue is a durable run-rate and multiple expands to ~2x sales on continued growth and partnership traction. Bear ~$1.75 reflects FY25 being a lumpy peak with reversion toward FY24 levels, forced dilutive raise, and continued cash burn.
On Wall Street's view (mixed): There is no Wall Street consensus target available (analyst_count is null), so no view to agree or disagree with directly. Absence of coverage is itself a negative signal for institutional adoption of the story.
What the news says · bullish
Pulsenmore (PLSM) has generated a cluster of positive catalysts in recent weeks, including selection to lead a $1M AI project within Israel's Healthcare AI Sandbox Programme, a partnership with Ouma's maternity care platform, and a $7.5M private placement from a healthcare investor. These developments signal growing commercial traction for its FDA-authorized home ultrasound device. However, meaningful headwinds temper the bullish read: the company is registering 3.1M warrant shares and Armistice is reselling 3.125M shares via a registered offering, both of which create near-term dilution and supply overhang. The stock has also been flagged as thinly traded and prone to momentum-driven whipsaws, suggesting retail speculation may be amplifying price moves beyond fundamental justification.
This analysis is from Jul 14, 2026. Markets move. Get the current read on PLSM and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.